Filtered By:
Education: Study
Management: Marketing
This page shows you your search results in order of date.
Order by Relevance | Date
Total 90 results found since Jan 2013.
Improve Your Memory A Whopping 27%
Traditional doctors think the best way to treat memory loss is with Big Pharma’s latest “breakthrough” drug. And when it’s proven not to work – not to mention dangerous – they simply pull another one out of their pocket…
That’s why I’m so concerned about the media buzz surrounding Lecanemab, one of the latest FDA-approved Alzheimer’s drug.
Because I want to be clear: It is NOT a wonder drug.
Lecanemab is a pharmaceutical product that, in clinical trials, resulted in a slight decline in cases of early Alzheimer’s when compared to a placebo. But…it was also associated with a long list of extremel...
Source: Al Sears, MD Natural Remedies - August 25, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Source Type: news
Append Medical Raises $4.35M in Initial Closing of Extended Series A Round
Funds will be used to complete the development of and support the First-in-Human Study of the Appligator for the Prevention of Stroke in Atrial Fibrillation Patients
OR YEHUDA, Israel, July 6, 2023 -- (Healthcare Sales & Marketing Network) -- Append M... Devices, Interventional, Cardiology, Venture Capital Append Medical, Appligator, left atrial appendage, Atrial Fibrillation
Source: HSMN NewsFeed - July 6, 2023 Category: Pharmaceuticals Source Type: news
NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104
Phase 1 safety study of NTS-104 is initiated in healthy volunteers
Compound is being developed for stroke and other Central Nervous System (CNS) injuries
ATLANTA, June 1, 2023 -- (Healthcare Sales & Marketing Network) -- NeuroTrauma Sciences, LLC (N... Biopharmaceuticals, Neurology, Drug Delivery NeuroTrauma Sciences, neurosteroid prodrug, stroke
Source: HSMN NewsFeed - June 1, 2023 Category: Pharmaceuticals Source Type: news
Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants
AbstractLarge-scaled post-marketing surveillance studies (PMSSs) of 4 direct oral anticoagulants (DOACs) for stroke prevention in non-valvular atrial fibrillation (AF) were conducted since 2011 in Japan, and the results of the last one have recently been published. Each reported a more than acceptable ischemic stroke prevention. The major bleeding rates were also acceptably low and comparable to each other in the PMSSs of dabigatran (J-dabigatran), rivaroxaban (XAPASS), and edoxaban (ETNA-AF-Japan). However, the incidence in PMSS of apixaban (STANDARD) was more than double the others. This finding appeared to contradict th...
Source: European Journal of Clinical Pharmacology - April 25, 2023 Category: Drugs & Pharmacology Source Type: research
9 Ways to Squeeze in More Steps Every Day
Every day for the past decade, I’ve tried to dethrone the family walking champ: my 67-year-old dad. Despite my youthful advantage—he has more than 30 years on me, as he’s quick to point out—I haven’t logged more steps than him once. I find this to be both mortifying and a point of vicarious pride; his fitness is remarkable. It’s also excellent motivation to find creative ways to finally out-walk him.
My dad and I compete using our favorite pedometer app, which displays each day’s steps in a bar graph. (While we both wear Apple Watches, we like the app best for logging the entire da...
Source: TIME: Health - January 12, 2023 Category: Consumer Health News Authors: Angela Haupt Tags: Uncategorized Exercise & Fitness healthscienceclimate Source Type: news
Scientists tie third clinical trial death to experimental Alzheimer ’s drug
As enthusiasm mounts for a new experimental antibody that appears to slow cognitive decline in some Alzheimer’s patients, a third death linked to the drug during its clinical testing may amplify concerns about its safety.
Science
has obtained medical records showing a 79-year-old Florida woman participating in an ongoing trial of the antibody died in mid-September after experiencing extensive brain swelling and bleeding, as well as seizures. Multiple neuroscientists who reviewed the records at
Science
’s request believe her death was likely caused by the antibody, lecanemab.
“The brain swelling and t...
Source: ScienceNOW - December 21, 2022 Category: Science Source Type: news
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration
Circulation. 2022 Nov 8;146(19):1461-1474. doi: 10.1161/CIRCULATIONAHA.121.058911. Epub 2022 Nov 7.ABSTRACTThe technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF s...
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Axel Brandes Stavros Stavrakis Ben Freedman Sotiris Antoniou Giuseppe Boriani A John Camm Clara K Chow Eric Ding Johan Engdahl Michael M Gibson Gregory Golovchiner Taya Glotzer Yutao Guo Jeff S Healey Mellanie T Hills Linda Johnson Gregory Y H Lip Trudie Source Type: research
Climate Experts Are Testing New Ways To Reach the People Most Affected by Extreme Heat
As heat waves become longer, hotter, and more widespread across the planet, human responses to them are becoming increasingly local and specialized.
Both scientific researchers and government officials are finding that the best strategies to keep cool are ones that are specially tailored to a community. That may seem obvious, given that outdoor laborers need different cooling resources than school teachers, for instance. But existing national and regional policies aren’t always that fine tuned—and they run the risk of wasting resources or missing the most vulnerable people.
[time-brightcove not-tgx=”tru...
Source: TIME: Health - July 19, 2022 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized climate climate change Climate Is Everything extreme weather healthscienceclimate Source Type: news
Conformal Medical Announces Launch of CONFORM Pivotal Trial
Study to support U.S. FDA approval of the novel CLAAS® implant for left atrial appendage occlusion (LAAO) and stroke prevention
NASHUA, N.H., June 17, 2022 -- (Healthcare Sales & Marketing Network) -- Conformal Medical, Inc., a medical device compa... Devices, Interventional, Cardiology Conformal Medical, CLAAS System, atrial fibrillation, LAAO
Source: HSMN NewsFeed - June 17, 2022 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
